Costs from Wind Down of Bevyxxa Activities	12 Months Ended
	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Costs from Wind Down of Bevyxxa Activities	Costs from Wind Down of Bevyxxa Activities Following the approval of Andexxa in May 2018, we made the business decision to focus our resources on the launch of Andexxa and significantly scaled back our commercial efforts on Bevyxxa. Throughout 2019, we engaged with potential business collaborators for Bevyxxa, and in the fourth quarter of 2019, we determined that it was unlikely that we will find a viable partner. Accordingly, we have begun to wind down Bevyxxa operations to eliminate future operational and financial obligations. Accordingly, we recorded a charge of $27.5 million as cost of sales which is comprised of an excess and obsolescence inventory charge of $13.7 million, a write-off of a long-term prepaid manufacturing asset of $7.8 million, an impairment charge for an intangible asset related to a payment made to Takeda of $3.7 million, and an accrual of firm purchase commitments of $2.3 million which we expect to settle in the next twelve months.